Key Record Dates Identifier: NCT02485691
Brief Title: Cabazitaxel Versus the Switch to Alternative AR-targeted Agent (Enzalutamide or Abiraterone) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients Previously Treated With Docetaxel and Who Rapidly Failed a Prior AR-targeted Agent (CARD)

First Submitted : June 26, 2015
First Submitted that Met QC Criteria : June 26, 2015
First Posted : June 30, 2015 (Estimate)

Last Update Submitted that Met QC Criteria : March 29, 2021
Last Update Posted : March 30, 2021